August 29, 2025

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’...

The ASCO Post

August 27, 2025

Clinical Trials and Research for Mantle Cell Lymphoma

Dana-Farber Cancer Institute is at the forefront of research in mantle cell lymphoma. We seek to advance more effective treatment options and reduce treatment side effects for patients with mantle cell lymphoma.

Dana-Farber

August 27, 2025

Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma

The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward impro...

The ASCO Post

August 27, 2025

Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma

Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, ...

The ASCO Post

August 25, 2025

Discontinuation and Resumption of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib sho...

The ASCO Post

August 25, 2025

High-Risk Rhabdomyosarcoma: Long-Term Outcomes With Maintenance Chemotherapy

Long-term follow-up of the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 trial was recently reported.

The ASCO Post

August 25, 2025

Rescue Therapy for Newly Diagnosed High-Grade Osteosarcoma

Could adding higher-dose ifosfamide to methotrexate, doxorubicin, and cisplatin improve outcomes for patients with newly diagnosed high-grade osteosarcoma who responded poorly to neoadjuvant chemother...

The ASCO Post

August 25, 2025

AACR 2025: AI-Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients

Researchers explored the potential of a novel artificial intelligence (AI)-based model to classify sarcomas among pediatric patients using digital pathology images alone, according to findings present...

The ASCO Post

August 25, 2025

Digital Histopathology and Automated Classification of Pediatric Sarcomas

With more than 50 different subtypes, pediatric soft-tissue sarcomas represent a broad category of disease. And given the rarity of these sarcomas, “it is difficult for pathologists to see a sufficien...

The ASCO Post